We demonstrated that celastrol treatment reduced total RNA m6A modification in pancreatic cancer cells by down-regulating METTL3 expression, especially decreased Claspin and Bcl-2 mRNA m6A modification, which induced the Claspin and Bcl-2 mRNA decay. The gene discussed is CLSPN; the disease is familial pancreatic carcinoma.